Price policy | Price per full course§ | Period covered | Remark |
Preferential price for the public or non-for-profit sector in developing countries | €45–55 (US$54–64)* | 2002–2008 | Price varied based on quantity purchased; minimum order quantity (MOQ) was imposed |
€80–110 (US$94–130) | 2009–2014 | ||
€100–140 (US$117–164)† | 2016 onwards | No MOQ, but price still varied based on quantity | |
Market price EU | €3000–12000 | 2012 | Direct order to the producer/distributor |
Market price US | US$33000-51000‡ | 2016 |
*This is the original price aimed for in the agreement between WHO and Asta Medica (1995) and published officially in the latest WHO Control of Leishmaniasis guidelines (2010).
†Price quoted by Knight Therapeutics for purchase by non-profit organisations Médecins Sans Frontières (MSF).
‡For 28 caps (https://www.drugs.com/price-guide/impavido). With the recommended dose, in the USA a patient weighing >45 kg needs 50 mg thrice daily, total 84 capsules.
§One full adult course of miltefosine monotherapy uses one pack containing 56 caps. The recommended dose is 2.5 mg/kg daily for 28 days (roughly 50 mg capsule twice daily for adults weighing >25 kg).